Includes the newest antidiabetic drugs that are cardioprotective, MACE, heart failure, the latest clinical trials, and treatment revolutions of therapy in both specialty areas of practice
New Clinical Practice Points and Take Home Summaries
1. Diabeto-Cardiology - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. Contributors - p. vii 8. Foreword - p. xi 9. Preface - p. xiii 10. Acknowledgments - p. xv 11. Braunwald’s Heart Disease Family of Books - p. xviii 12. PART I: DIABETES MELLITUS - p. P1 13. 1. Definition and Epidemiology of Type 2 Diabetes Mellitus - p. 1 14. 2. Insulin Resistance: Pathophysiology, Molecular Mechanisms, and Genetic Insights - p. 9 15. 3. Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus - p. 25 16. 4. Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes - p. 48 17. 5. Type 1 Diabetes: Pathophysiology and Treatment Considerations for Cardiovascular Risk and Disease - p. 61 18. PART II: CARDIOVASCULAR COMPLICATIONS OFTYPE 2 DIABETES - p. P81 19. 6. Epidemiology of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease - p. 81 20. 7. Pathology and Vascular Biology of Atherosclerosis in Patients With Type 2 Diabetes - p. 97 21. 8. Risk Stratification Among Patients With Type 2 Diabetes With or at Risk for Atherosclerotic Cardiovascular Disease - p. 131 22. 9. Epidemiology and Pathophysiology of Heart Failure With Preserved and With Reduced Ejection Fraction in Patients With Type 2 Diabetes - p. 142 23. PART III: EFFECTS OF ANTIHYPERGLYCEMIC THERAPIES FOR TYPE 2 DIABETES ON CARDIOVASCULAR AND KIDNEY OUTCOMES - p. P151 24. 10. Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 151 25. 11. Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future - p. 170 26. 12. Cardiovascular and Kidney Effects of Sodium Glucose Cotransporter Inhibitors - p. 180 27. 13. Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists - p. 193 28. 14. Antihyperglycemic Medications With Proven Cardiovascular Safety - p. 204 29. 15. Prevention of Heart Failure in People With Diabetes - p. 217 30. 16. Treatment of Patients With Reduced and With Preserved Ejection Fraction Heart Failure in Patients With Type 2 Diabetes - p. 231 31. PART IV: MANAGEMENT OF CORONARY HEART DISEASE RISK CHRONIC AND ACUTE CORONARY SYNDROMES IN PATIENTS WITH TYPE 2 DIABETES - p. P245 32. 17. Effect of Lifestyle Interventions on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 245 33. 18. Effect of Blood Pressure Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 260 34. 19. Effect of Lipid Management on Coronary Heart Disease Risk in Persons With Type 2 Diabetes - p. 273 35. 20. Effect of Antithrombotic Therapy on Coronary Heart Disease Risk in People With Diabetes Mellitus - p. 284 36. 21. Role of Percutaneous Coronary Intervention in Patients With Diabetes - p. 297 37. PART V: OTHER CARDIOVASCULARCONSIDERATIONS FOR PATIENTS WITH TYPE 2 DIABETES - p. P309 38. 22. Peripheral Artery Disease in Persons With Type 2 Diabetes - p. 309 39. 23. Cerebrovascular Disease in Persons With Diabetes - p. 324 40. 24. Atrial Fibrillation in Persons With Type 2 Diabetes - p. 342 41. 25. Chronic Kidney Disease: Implications for Cardiovascular Risk and Management in Patients With Type 2 Diabetes - p. 353 42. 26. Disparities in Type 2 Diabetes Risk, Cardiovascular Consequences, and Care: Females, Racial/Ethnic Minorities, and the Elderly - p. 369 43. 27. The Quality Chasm and the Need for Implementation Science to Reduce Cardiovascular Disease Risk in Type 2 Diabetes - p. 381 44. Index - p. 387
Includes the newest antidiabetic drugs that are cardioprotective, MACE, heart failure, the latest clinical trials, and treatment revolutions of therapy in both specialty areas of practice
New Clinical Practice Points and Take Home Summaries
1. Diabeto-Cardiology - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. Contributors - p. vii 8. Foreword - p. xi 9. Preface - p. xiii 10. Acknowledgments - p. xv 11. Braunwald’s Heart Disease Family of Books - p. xviii 12. PART I: DIABETES MELLITUS - p. P1 13. 1. Definition and Epidemiology of Type 2 Diabetes Mellitus - p. 1 14. 2. Insulin Resistance: Pathophysiology, Molecular Mechanisms, and Genetic Insights - p. 9 15. 3. Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus - p. 25 16. 4. Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes - p. 48 17. 5. Type 1 Diabetes: Pathophysiology and Treatment Considerations for Cardiovascular Risk and Disease - p. 61 18. PART II: CARDIOVASCULAR COMPLICATIONS OFTYPE 2 DIABETES - p. P81 19. 6. Epidemiology of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease - p. 81 20. 7. Pathology and Vascular Biology of Atherosclerosis in Patients With Type 2 Diabetes - p. 97 21. 8. Risk Stratification Among Patients With Type 2 Diabetes With or at Risk for Atherosclerotic Cardiovascular Disease - p. 131 22. 9. Epidemiology and Pathophysiology of Heart Failure With Preserved and With Reduced Ejection Fraction in Patients With Type 2 Diabetes - p. 142 23. PART III: EFFECTS OF ANTIHYPERGLYCEMIC THERAPIES FOR TYPE 2 DIABETES ON CARDIOVASCULAR AND KIDNEY OUTCOMES - p. P151 24. 10. Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 151 25. 11. Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future - p. 170 26. 12. Cardiovascular and Kidney Effects of Sodium Glucose Cotransporter Inhibitors - p. 180 27. 13. Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists - p. 193 28. 14. Antihyperglycemic Medications With Proven Cardiovascular Safety - p. 204 29. 15. Prevention of Heart Failure in People With Diabetes - p. 217 30. 16. Treatment of Patients With Reduced and With Preserved Ejection Fraction Heart Failure in Patients With Type 2 Diabetes - p. 231 31. PART IV: MANAGEMENT OF CORONARY HEART DISEASE RISK CHRONIC AND ACUTE CORONARY SYNDROMES IN PATIENTS WITH TYPE 2 DIABETES - p. P245 32. 17. Effect of Lifestyle Interventions on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 245 33. 18. Effect of Blood Pressure Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 260 34. 19. Effect of Lipid Management on Coronary Heart Disease Risk in Persons With Type 2 Diabetes - p. 273 35. 20. Effect of Antithrombotic Therapy on Coronary Heart Disease Risk in People With Diabetes Mellitus - p. 284 36. 21. Role of Percutaneous Coronary Intervention in Patients With Diabetes - p. 297 37. PART V: OTHER CARDIOVASCULARCONSIDERATIONS FOR PATIENTS WITH TYPE 2 DIABETES - p. P309 38. 22. Peripheral Artery Disease in Persons With Type 2 Diabetes - p. 309 39. 23. Cerebrovascular Disease in Persons With Diabetes - p. 324 40. 24. Atrial Fibrillation in Persons With Type 2 Diabetes - p. 342 41. 25. Chronic Kidney Disease: Implications for Cardiovascular Risk and Management in Patients With Type 2 Diabetes - p. 353 42. 26. Disparities in Type 2 Diabetes Risk, Cardiovascular Consequences, and Care: Females, Racial/Ethnic Minorities, and the Elderly - p. 369 43. 27. The Quality Chasm and the Need for Implementation Science to Reduce Cardiovascular Disease Risk in Type 2 Diabetes - p. 381 44. Index - p. 387
